PF3D7_1011400

PF3D7_1011400 encodes the chymotrypsin-like (β5) catalytic subunit of the Plasmodium falciparum 20S proteasome, whose active-site architecture was resolved by cryo-EM and shown to differ in substrate specificity from the human proteasome, establishing a structural basis for species-selective inhibition (PMID:26863983). The β5 active site sits at the β5/β6/β3 subunit interface and contains the catalytic threonine that defines its proteolytic activity (PMID:39084225). This subunit is the primary target of a series of species-selective antimalarial inhibitors—amino-amide boronates, macrocyclic peptides, piperidine carboxamides, and carboxypiperidines—that engage the β5 site (in some cases together with β2) with greater affinity for Pf20S than for human proteasome isoforms, and whose biochemical inhibition of β5 correlates directly with parasite killing across blood, liver, and sexual stages (PMID:34548400, PMID:38097652, PMID:39084225, PMID:41148577). Point mutations selected in the β5 active site confer resistance to these inhibitors, and a neighboring β6 mutation (A117D) reshapes β5/β2 inhibitor binding, placing β5 at the center of both drug action and resistance/collateral-sensitivity mechanisms (PMID:38097652, PMID:39084225). Within the 20S core, β5 is a constituent catalytic subunit of the complex that is capped asymmetrically by the PfPA28 regulator (PMID:31384003). Beyond its role as a catalytic subunit of the 20S proteasome and its function as a validated antimalarial drug target, no additional mechanistic detail specific to PF3D7_1011400 has been characterized in the available corpus.

1. 2016 High

   The question of why the parasite proteasome could be targeted selectively over the human enzyme was answered by resolving the β5 active-site architecture and showing its substrate specificity differs from the human proteasome.

   Evidence 3.6 Å cryo-EM structure with fluorogenic peptide substrate profiling and inhibitor binding assays in P. falciparum

   PMID:26863983

   Open questions at the time

   • Designed inhibitors in this study preferentially hit β2 rather than β5, leaving β5-selective inhibition unproven at this stage
   • No in vivo validation of β5 targeting
2. 2019 High

   The structural context of β5 within the assembled 20S core and its regulation was defined by resolving the Pf20S in complex with the PfPA28 regulatory cap.

   Evidence Single-particle cryo-EM (3.9/3.8 Å), crystallography of PfPA28, SAXS and molecular dynamics in P. falciparum

   PMID:31384003

   Open questions at the time

   • Functional consequence of asymmetric PA28 capping for β5 catalytic activity not established
   • Does not address β5 as a drug target
3. 2021 High

   Whether β5 could be selectively drugged for fast-acting antimalarial effect was answered by showing amino-amide boronates bind the β5 active site with greater affinity than human 20S and kill parasites.

   Evidence Cryo-EM of Pf20S–inhibitor complex, biochemical β5 activity assays, in vitro growth inhibition, and SCID mouse model in P. falciparum and P. vivax

   PMID:34548400

   Open questions at the time

   • Resistance liability of β5-targeting boronates not yet mapped in this study
   • Covalent boronate mechanism differs from later reversible inhibitors
4. 2023 High

   The role of β5 in a dual-subunit binding mode and in resistance was clarified by showing a macrocyclic peptide engages both β2 and β5 and that a β6 A117D mutation reshapes inhibitor binding at these sites.

   Evidence Cryo-EM of wild-type and β6A117D mutant Pf20S–inhibitor complexes, parasite killing assays, and resistance selection in P. falciparum and P. cynomolgi

   PMID:38097652

   Open questions at the time

   • Relative contribution of β5 versus β2 engagement to parasite killing not deconvolved
   • Mechanism of collateral sensitivity not fully resolved
5. 2024 High

   Direct causal linkage between β5 inhibition and parasite death was established by mapping resistance mutations to the β5 active site and showing β5 activity inhibition correlates with killing without hitting human proteasome.

   Evidence Resistance selection with sequencing, cryo-EM of Pf20S–SW584 revealing a non-covalent pocket at the β5/β6/β3 interface, biochemical β5 assays and mouse model in P. falciparum

   PMID:39084225

   Open questions at the time

   • The SW584 binding pocket is distal to the catalytic threonine, so allosteric mechanism of inhibition is not fully defined
6. 2025 Medium

   Whether selective engagement of β5 alone suffices for potency was addressed by showing optimized carboxypiperidine reversible inhibitors bind β5 and achieve nanomolar blood-stage potency with human selectivity.

   Evidence Cryo-EM of Pf20S–inhibitor complex, SAR, in vitro growth inhibition and PK assays in P. falciparum

   PMID:41148577

   Open questions at the time

   • Single-lab study without independent replication
   • In vivo efficacy and resistance profile of this chemotype not reported here
7. 2011 Low

   Early evidence that inhibiting the parasite proteasome disrupts protein turnover across stages came from thiostrepton-induced ubiquitinated protein accumulation and gametocyte elimination.

   Evidence Ubiquitinated protein accumulation assay, expression profiling, and stage-specific growth inhibition in P. falciparum

   PMID:21245445

   Open questions at the time

   • β5 subunit not individually distinguished from other catalytic subunits
   • Indirect readout of proteasome inhibition rather than direct β5 activity measurement

• How β5 catalytic activity is regulated within the assembled 20S core and how its inhibition selectively disrupts parasite proteostasis across the life cycle remains unresolved.
• No mapping of endogenous β5 substrate repertoire in vivo
• Functional link between PA28 capping and β5 activity not established
• Mechanism connecting distal non-covalent inhibitor binding to catalytic inhibition unclear